Ciltacabtagene autoleucel (cilta-cel), a B cell maturation antigen (BCMA)-targeting therapy, appears to show promising activity among patients with previously treated multiple myeloma (MM), according to research presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.
Cilta-cel, a chimeric antigen receptor (CAR) T-cell therapy, expresses 2 BCMA-directed antibodies. For the phase 2 CARTITUDE-2 study (ClinicalTrials.gov Identifier: NCT04133636), researchers are evaluating the safety and efficacy of cilta-cel in several cohorts of patients with MM.
In this poster, researchers presented data from Cohort A of CARTITUDE-2, which included patients with progressive MM after 1 to 3 prior lines of therapy. No patients had received previous exposure to any BCMA-targeting therapy. Patients received a single cilta-cel infusion.
A total of…